MedTrace Logo

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

NCT06957431 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-10-24

No results posted yet for this study

Summary

The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.

Conditions

  • Advanced Leiomyosarcoma
  • Adipocytic Sarcoma
  • Advanced Liposarcoma

Interventions

DRUG

Zanzalintinib

Supplied by Exelixis, Inc.

DRUG

Eribulin

1.1 mg/m\^2 dose.

Sponsors & Collaborators

  • Exelixis

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Mia C Weiss, M.D. · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-22
Primary Completion
2028-11-30
Completion
2033-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06957431 on ClinicalTrials.gov